A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome

Status:	Active, not recruiting
Conditions:	Hospital, Pulmonary
Therapuetic Areas:	Pulmonary / Respiratory Diseases, Other
Healthy:	No
Age Range:	18 - 90
Updated:	1/11/2019
Start Date:	January 2016
End Date:	September 2019

A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome

A study to examine the safety (and potential efficacy) of the adult stem cell investigational
product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The
primary hypothesis is that MultiStem will be safe in ARDS patients.

Inclusion Criteria:

- Diagnosis of moderate to severe ARDS, as defined by the Berlin definition, requiring
an endotracheal or tracheal tube

- Able to receive investigational medicinal product within 96 hours of meeting the last
of the ARDS diagnosis criterion

Exclusion Criteria:

- Concurrent illness that shortens life expectancy to less than 6 months

- Other serious medical or psychiatric illness

We found this trial at

sites

University of Pittsburgh Medical Center

200 Lothrop St
Pittsburgh, Pennsylvania 15213